<DOC>
	<DOCNO>NCT01667796</DOCNO>
	<brief_summary>This pilot study oral vitamin D supplementation determine patient Multiple Sclerosis ( MS ) healthy individual attain similar increase serum 25-hydroxyvitamin D level . The investigator also assess whether immunologic relevant gene expression response oral vitamin D supplementation differs patient MS healthy control .</brief_summary>
	<brief_title>Pharmacokinetics Vitamin D Multiple Sclerosis Health</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Female Healthy multiple sclerosis Aged 18 60 Body mass index 18 kg/m2 30 kg/m2 Screening 25hydroxyvitamin D level ≤ 75 nmol/L ( 30 ng/mL ) White race NonHispanic ethnicity Willing use birth control study Willing use tan bed study If subject multiple sclerosis : Relapsingremitting MS , define McDonald 2005 criterion Screening Expanded Disability Status Scale score ≤ 3.0 Using medication MS , take Copaxone , ( glatiramer acetate ) , interferon , natalizumab Pregnant nursing Taking multivitamin &amp; unwilling remain study Taking cod liver oil &amp; unwilling remain study On fatrestricted diet History renal disease nephrolithiasis ( kidney stone ) History liver disease Taking thiazide diuretic History hyperthyroidism History infection Mycobacterium species History sarcoidosis History cancer History cardiac disease History HIV History gastrointestinal disorder Taking medication interfere gastrointestinal absorption Cigarette smoker past month Use illicit drug past month Use steroid past month History hypercalcemia , screen serum calcium ≤ 10 mg/dL ( UCSF ) ≤ 10.7 mg/dL ( Johns Hopkins ) History hypercalciuria Evidence anemia ( Hgb &lt; 11.0 g/dL ) History serious medical condition Taking medication involve P450 system may interact vitamin D ( digoxin , diltiazem , verapamil , cimetidine , heparin , lowmolecular weight heparin ) Other concern safety perspective treat physician If subject MS : History major heat sensitivity ( lead sunavoidant behavior )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Healthy control</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Vitamin D</keyword>
</DOC>